{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:40:09Z","timestamp":1776692409429,"version":"3.51.2"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National key research and development program","doi-asserted-by":"crossref","award":["2016YFC0902800"],"award-info":[{"award-number":["2016YFC0902800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Key Project of Natural Science Foundation of China","award":["81530006"],"award-info":[{"award-number":["81530006"]}]},{"name":"Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research","award":["2019CXJQ01"],"award-info":[{"award-number":["2019CXJQ01"]}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81870112"],"award-info":[{"award-number":["81870112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770171"],"award-info":[{"award-number":["81770171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Samuel Waxman Cancer Research Foundation"},{"name":"Innovative research team of high-level local universities in Shanghai"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic leukemia (B-ALL). The BCR-ABL tyrosine kinase inhibitors (TKIs) have shown a remarkable clinical activity in patients with CML, but their efficacy in treating Ph<jats:sup>+<\/jats:sup> B-ALL is limited. Identifying additional therapeutic targets is important for the effective treatment of Ph<jats:sup>+<\/jats:sup> B-ALL.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Activation of the JNK signaling pathway in human and mouse BCR-ABL<jats:sup>+<\/jats:sup> B-ALL cells with or without dasatinib treatment was analyzed by Western blotting. JNK was inhibited either by RNA interference or chemical inhibitors, such as JNK-IN-8. The effect of JNK inhibition with or without BCR-ABL TKI dasatinib on BCR-ABL<jats:sup>+<\/jats:sup> B-ALL cells was analyzed by the CellTiter-Glo\u00ae Luminescent Cell Viability Assay. The in vivo effects of JNK-IN-8 and dasatinib alone or in combination were tested using a BCR-ABL induced B-ALL mouse model.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We found that the c-JUN N-terminal kinase (JNK) signaling pathway is abnormally activated in both human and mouse BCR-ABL<jats:sup>+<\/jats:sup> B-ALL cells, but the BCR-ABL TKI does not inhibit JNK activation in these cells. Inhibition of JNK, either by RNAi-mediated downregulation or by JNK inhibitors, could significantly reduce viability of Ph<jats:sup>+<\/jats:sup> B-ALL cells. JNK inhibition by RNAi-mediated downregulation or JNK inhibitors also showed a synergistic effect with the BCR-ABL TKI, dasatinib, in killing Ph<jats:sup>+<\/jats:sup> B-ALL cells in vitro. Furthermore, a potent JNK inhibitor, JNK-IN-8, in combination with dasatinib markedly improved the survival of mice with BCR-ABL induced B-ALL, as compared to the treatment with dasatinib alone.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our findings indicate that simultaneously targeting both BCR-ABL and JNK kinase might serve as a promising therapeutic strategy for Ph<jats:sup>+<\/jats:sup> B-ALL.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13045-020-00912-3","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T10:04:12Z","timestamp":1592474652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition"],"prefix":"10.1186","volume":"13","author":[{"given":"Xinhua","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhizhou","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruibao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"912_CR1","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","volume":"20","author":"DT Teachey","year":"2019","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019;20:e142\u201354.","journal-title":"Lancet Oncol"},{"key":"912_CR2","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"912_CR3","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"912_CR4","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","volume":"28","author":"M Arico","year":"2010","unstructured":"Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28:4755\u201361.","journal-title":"J Clin Oncol"},{"key":"912_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O\u2019Brien S, Nicaise C, Bleickardt E, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531\u201341.","journal-title":"N Engl J Med"},{"key":"912_CR6","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110:2309\u201315.","journal-title":"Blood"},{"key":"912_CR7","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.073","volume":"6","author":"S Chiaretti","year":"2014","unstructured":"Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6:e2014073.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"912_CR8","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coude MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774\u201382.","journal-title":"Blood"},{"key":"912_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","volume":"18","author":"MA Gregory","year":"2010","unstructured":"Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt\/Ca2+\/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 2010;18:74\u201387.","journal-title":"Cancer Cell"},{"key":"912_CR10","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009;48:964\u201370.","journal-title":"Acta Oncol"},{"key":"912_CR11","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1172\/JCI86249","volume":"126","author":"C Guignabert","year":"2016","unstructured":"Guignabert C, Phan C, Seferian A, Huertas A, Tu L, Thuillet R, Sattler C, Le Hiress M, Tamura Y, Jutant EM, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126:3207\u201318.","journal-title":"J Clin Invest"},{"key":"912_CR12","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279\u201390.","journal-title":"Oncogene"},{"key":"912_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","volume":"75","author":"M Cargnello","year":"2011","unstructured":"Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75:50\u201383.","journal-title":"Microbiol Mol Biol Rev"},{"key":"912_CR14","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/s41388-018-0582-8","volume":"38","author":"S Papa","year":"2019","unstructured":"Papa S, Choy PM, Bubici C. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene. 2019;38:2223\u201340.","journal-title":"Oncogene"},{"key":"912_CR15","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/sj.onc.1210392","volume":"26","author":"M Raman","year":"2007","unstructured":"Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26:3100\u201312.","journal-title":"Oncogene"},{"key":"912_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/mc.20348","volume":"46","author":"AM Bode","year":"2007","unstructured":"Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog. 2007;46:591\u20138.","journal-title":"Mol Carcinog"},{"key":"912_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537\u201349.","journal-title":"Nat Rev Cancer"},{"key":"912_CR18","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1038\/onc.2016.417","volume":"36","author":"X Xie","year":"2017","unstructured":"Xie X, Kaoud TS, Edupuganti R, Zhang T, Kogawa T, Zhao Y, Chauhan GB, Giannoukos DN, Qi Y, Tripathy D, et al. c-JUN N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-JUN. Oncogene. 2017;36:2599\u2013608.","journal-title":"Oncogene"},{"key":"912_CR19","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1182\/blood.V92.7.2450","volume":"92","author":"GS Burgess","year":"1998","unstructured":"Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, Kraft AS, Nakshatri H, Boswell HS. Regulation of the c-JUN gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-JUN N-terminal kinase. Blood. 1998;92:2450\u201360.","journal-title":"Blood"},{"key":"912_CR20","doi-asserted-by":"publisher","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","volume":"92","author":"AB Raitano","year":"1995","unstructured":"Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A. 1995;92:11746\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"912_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/ng946","volume":"32","author":"P Hess","year":"2002","unstructured":"Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-JUN NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet. 2002;32:201\u20135.","journal-title":"Nat Genet"},{"key":"912_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21037\/sci.2016.11.06","volume":"3","author":"D Li","year":"2016","unstructured":"Li D, Zhao X, Zhang R, Jiao B, Liu P, Ren R. BCR\/ABL can promote CD19(+) cell growth but not render them long-term stemness. Stem Cell Investig. 2016;3:85.","journal-title":"Stem Cell Investig"},{"key":"912_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/1535-7163.MCT-16-0419","volume":"16","author":"M Wu","year":"2017","unstructured":"Wu M, Huang J, Zhang J, Benes C, Jiao B, Ren R. N-Arachidonoyl dopamine inhibits NRAS neoplastic transformation by suppressing its plasma membrane translocation. Mol Cancer Ther. 2017;16:57\u201367.","journal-title":"Mol Cancer Ther"},{"key":"912_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.442","volume":"8","author":"X Xiao","year":"2017","unstructured":"Xiao X, Li H, Jin H, Jin J, Yu M, Ma C, Tong Y, Zhou L, Lei H, Xu H, et al. Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's lymphoma. Cell Death Dis. 2017;8:e3050.","journal-title":"Cell Death Dis"},{"key":"912_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"912_CR26","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18:930\u20137.","journal-title":"Clin Cancer Res"},{"key":"912_CR27","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1182\/blood-2014-12-615906","volume":"125","author":"A Nonami","year":"2015","unstructured":"Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, et al. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 2015;125:3133\u201343.","journal-title":"Blood"},{"key":"912_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.chembiol.2011.11.010","volume":"19","author":"T Zhang","year":"2012","unstructured":"Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro SB, Machleidt T, Xie T, Marto JA, Kim N, Sim T, et al. Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012;19:140\u201354.","journal-title":"Chem Biol"},{"key":"912_CR29","doi-asserted-by":"publisher","first-page":"32580","DOI":"10.1074\/jbc.274.46.32580","volume":"274","author":"K Noguchi","year":"1999","unstructured":"Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem. 1999;274:32580\u20137.","journal-title":"J Biol Chem"},{"key":"912_CR30","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2004-10-3819","volume":"106","author":"M Gururajan","year":"2005","unstructured":"Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD. Bondada S: c-JUN N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood. 2005;106:1382\u201391.","journal-title":"Blood"},{"key":"912_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature09732","volume":"471","author":"H Inuzuka","year":"2011","unstructured":"Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471:104\u20139.","journal-title":"Nature"},{"key":"912_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2019.03.005","volume":"35","author":"N Luong-Gardiol","year":"2019","unstructured":"Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, Irmisch A, Curtet S, Angelov GS. Danilo M, et al: gamma-catenin-dependent signals maintain BCR-ABL1(+) B cell acute lymphoblastic leukemia. Cancer Cell. 2019;35:649\u201363 e610.","journal-title":"Cancer Cell"},{"key":"912_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u201373.","journal-title":"Nature"},{"key":"912_CR34","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Foa","year":"2011","unstructured":"Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, Elia L, Paoloni F, Fazi P, Cimino G, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521\u20138.","journal-title":"Blood"},{"key":"912_CR35","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","volume":"39","author":"C Sillaber","year":"2009","unstructured":"Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A, Herndlhofer S, Tschachler E, Superti-Furga G, Jager U, Valent P. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u2009mg daily. Eur J Clin Invest. 2009;39:1098\u2013109.","journal-title":"Eur J Clin Invest"},{"key":"912_CR36","doi-asserted-by":"crossref","first-page":"682","DOI":"10.18632\/genesandcancer.155","volume":"8","author":"DN Dhanasekaran","year":"2017","unstructured":"Dhanasekaran DN, Reddy EP. JNK-signaling: a multiplexing hub in programmed cell death. Genes Cancer. 2017;8:682\u201394.","journal-title":"Genes Cancer"},{"key":"912_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/cr.2008.86","volume":"18","author":"X Mao","year":"2008","unstructured":"Mao X, Yu CR, Li WH, Li WX. Induction of apoptosis by shikonin through a ROS\/JNK-mediated process in Bcr\/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res. 2008;18:879\u201388.","journal-title":"Cell Res"},{"key":"912_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ng1343","volume":"36","author":"Y Hu","year":"2004","unstructured":"Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453\u201361.","journal-title":"Nat Genet"},{"key":"912_CR39","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1535-7163.MCT-09-0408","volume":"8","author":"J Cui","year":"2009","unstructured":"Cui J, Wang Q, Wang J, Lv M, Zhu N, Li Y, Feng J, Shen B, Zhang J. Basal c-JUN NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells. Mol Cancer Ther. 2009;8:3214\u201322.","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00912-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-020-00912-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-020-00912-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T23:29:18Z","timestamp":1623972558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-020-00912-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1186\/s13045-020-00912-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"6 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by The Animal Care & Welfare Committee of Ruijin Hospital affiliated to Shanghai Jiao tong University School of Medicine. Patient samples preparation was approved by the Institutional Review Board of the Ruijin Hospital affiliated to Shanghai Jiao tong University School of Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}